Table 5.
Differential expression of the miRNA level in the serum from controls and OA patients analyzed by quantitative real-time PCR
| miR | Prevalent OA (−), median (IQR 25–75%) | Prevalent OA (+), median (IQR 25–75%) | p value | Incident OA (−), median (IQR 25–75%) | Incident OA (+), median (IQR 25–75%) | p value |
|---|---|---|---|---|---|---|
| 126-3p | 1.08 (0.85–1.36) | 1.06 (0.89–1.30) | 0.75 | 0.89 (0.80–1.04) | 0.91 (0.73–1.23) | 0.66 |
| 1299 | 0.28 (0.16–1.73) | 0.33 (0.16–2.35) | 0.80 | 0.27 (0.14–11.36) | 0.34 (0.12–0.90) | 0.82 |
| 132-3p | 1.37 (0.71–2.12) | 0.86 (0.43–1.85) | 0.12 | 0.91 (0.63–1.19) | 1.04 (0.59–1.97) | 0.70 |
| 139-5p | 1.50 (0.34–3.63) | 2.09 (0.23–8.24) | 0.27 | 0.28 (0.05–1.98) | 0.81 (0.14–6.59) | 0.16 |
| 146a-5p | 0.85 (0.62–1.03) | 1.12 (0.73–1.46) | 0.015 | 0.83 (0.70–0.97) | 0.88 (0.62–1.29) | 0.94 |
| 16-5p | 0.92 (0.72–1.82) | 0.85 (0.61–1.50) | 0.35 | 0.98 (0.59–1.24) | 1.01 (0.73–1.44) | 0.33 |
| 184 | 0.95 (0.64–2.18) | 1.05 (0.58–2.38) | 0.86 | 0.69 (0.41–1.76) | 0.80 (0.31–1.24) | 0.89 |
| 186-5p | 1.09 (0.81–1.39) | 1.03 (0.79–1.31) | 0.47 | 0.82 (0.72–1.09) | 1.05 (0.82–1.46) | 0.09 |
| 195-5p | 0.91 (0.75–1.42) | 0.90 (0.52–1.60) | 0.50 | 0.93 (0.65–1.24) | 1.03 (0.69–1.47) | 0.42 |
| 199a-3p | 0.96 (0.77–1.12) | 0.93 (0.82–1.47) | 0.46 | 0.89 (0.76–0.98) | 1.00 (0.71–1.39) | 0.13 |
| 200a-3p | 0.84 (0.56–1.93) | 1.00 (0.58–1.57) | 0.62 | 0.72 (0.49–1.06) | 0.73 (0.48–1.43) | 0.93 |
| 29a-3p | 1.12 (0.76–1.44) | 1.00 (0.68–1.38) | 0.40 | 1.12 (0.63–1.35) | 0.84 (0.61–1.50) | 0.66 |
| 29b-3p | 1.14 (0.81–1.74) | 1.06 (0.81–1.51) | 0.38 | 1.02 (0.71–1.42) | 0.99 (0.67–1.53) | 0.93 |
| 29c-3p | 1.04 (0.66–1.59) | 0.91 (0.64–1.59) | 0.63 | 0.73 (0.44–1.16) | 0.86 (0.45–1.56) | 0.35 |
| 345-5p | 3.10 (0.10–10.01) | 2.81 (0.22–7.12) | 0.99 | 0.53 (0.05–2.11) | 1.14 (0.09–5.97) | 0.24 |
| 375 | 1.57 (0.20–4.05) | 1.40 (0.48–4.77) | 0.56 | 0.98 (0.26–2.99) | 0.86 (0.24–3.07) | 0.91 |
| 885-5p | 1.40 (0.60–2.16) | 1.16 (0.28–2.40) | 0.48 | 0.97 (0.49–2.85) | 1.54 (0.70–2.38) | 0.54 |
| 93-5p | 1.11 (0.79–1.51) | 0.91 (0.68–1.38) | 0.21 | 1.07 (0.79–1.17) | 1.19 (0.79–1.53) | 0.25 |
| let-7e-5p | 1.15 (0.41–4.52) | 2.28 (0.64–5.83) | 0.25 | 1.36(0.78–2.72) | 1.37 (0.36–2.36) | 0.89 |
The miRNA levels were analyzed in the serum from individuals of the validation cohort, and differences in the serum miRNA levels are reported according to the prevalent or incident OA status. The relative miRNA level was used for the statistical comparisons. IQR = interquartile range [(+) = women with prevalent or incident knee OA, (−) = controls]